Piramal Healthcare

Piramal Enterprises Limited is the flagship company of the Piramal Group.  Starting from the mid-1980s, PEL has shifted its focus from the textiles industry, and established its entrepreneurial credentials in Pharma, Information Management, and Financial Services. It has grown organically and inorganically and often made contrarian business calls.  When Indian pharmaceutical industry was focused on international generics, we invested in domestic formulation businesses.

Post : Sr. Principal Scientist

Piramal Healthcare Limited A major force in the pharmaceuticals and healthcare segment, Piramal Healthcare Limited, incorporating Healthcare Solutions & Pharma Solutions, has an unequivocal vision – to become the most admired pharmaceutical company, with leadership in market share and profits.

Post : Research Scientist

Piramal Group is a global business conglomerate with interests in Pharma, Financial Services, Information Management, Glass Packaging and Real Estate.  The Group’s flagship company, Piramal Enterprises Limited, generates more than 51% of its revenues from international markets.  Piramal Foundation runs sustainable development programmes across healthcare, education and water resources. Piramal Sarvajal and Piramal Swasthya, initiatives of the Foundation, are case studies at the Harvard Business School.

Post : Senior Principal Scientist

Piramal Enterprises Ltd. provides a world class integrated drug discovery services platform from our state-of-the-art research Centre in India. PDS's delivery model has a proven track record of providing a step change in the effectiveness of drug discovery for a range of global pharmaceuticals and biotechnology companies operating at the forefront of drug discovery. PDS understands that early and intensive evaluation of the molecules based on thorough communications and rapid decision-making will lead to a high throughput of successful drug-like compounds.

Post: Executive - Production

Piramal Healthcare Limited A major force in the pharmaceuticals and healthcare segment, Piramal Healthcare Limited, incorporating Healthcare Solutions & Pharma Solutions, has an unequivocal vision – to become the most admired pharmaceutical company, with leadership in market share and profits.

Post : Production Executive_MAHA - (1800002Y)

Piramal Healthcare Ltd, a Piramal Group company, is a globally integrated healthcare company that fulfills unmet medical needs across the world. It has a growth track record of above 29% CAGR since 1988. Piramal Healthcare had consolidated revenues of US$ 656 million in FY2009. PHL is currently ranked 4th in the Indian market with a diverse product portfolio spanning several therapeutic areas. It is also one of the largest custom manufacturing companies with a global footprint of assets across North America, Europe and Asia.

Post : Exe. R&D (Commercial)

Piramal Healthcare Ltd, a Piramal Group company, is a globally integrated healthcare company that fulfills unmet medical needs across the world. It has a growth track record of above 29% CAGR since 1988. Piramal Healthcare had consolidated revenues of US$ 656 million in FY2009. PHL is currently ranked 4th in the Indian market with a diverse product portfolio spanning several therapeutic areas. It is also one of the largest custom manufacturing companies with a global footprint of assets across North America, Europe and Asia.

Post : Executive - QA

Piramal Healthcare Limited A major force in the pharmaceuticals and healthcare segment, Piramal Healthcare Limited, incorporating Healthcare Solutions & Pharma Solutions, has an unequivocal vision – to become the most admired pharmaceutical company, with leadership in market share and profits.

Post : Executive - Stores

The flagship company of the Piramal Group, Piramal Enterprises Ltd. (PEL), has business interests in Pharma, Information Management, and Financial Services verticals of the group.  Towards the late 80s, we shifted our focus from textile to pharmaceuticals. We chose to invest significantly in the domestic formulation development business, while other companies in the industry concentrated on international generics. Our efforts proved successful with a track record of approximately 23% revenue CAGR. In 2010, our strategy accomplished a sale of its domestic formulations business at an unprecedented value of ~9x sales and ~30x EBITDA.